

CORPORATE FACT SHEET



As of February 11, 2008

OFFICES

45 Moulton Street
Cambridge, MA 02138
e-mail: info@curis.com
URL: www.curis.com
Phone: 617-503-6500
Fax: 617-503-6501

BUSINESS

Drug Development with a small molecule cancer focus

FOUNDED

2000

OWNERSHIP

Publicly traded on the NASDAQ (CRIS)

SHARES

63,241,561 (at December 31, 2007)

EMPLOYEES

Approximately 45

COLLABORATIONS

- (1) Genentech: Hedgehog Antagonist (Cancer)
- (2) Genentech: Wnt signaling pathway (Cancer)
- (3) Wyeth: Hedgehog Agonist (Stroke/Nervous System Disorders)

TRANSFER AGENT

Mellon Investor Service LLC
85 Challenger Road
Ridgefield Park, NJ 07660
Phone: 800-288-9541
www.mellon-investor.com

Please see Curis' Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other filings that we periodically make with the Securities & Exchange Commission for additional information on the company and its status based on filing date.

MANAGEMENT TEAM

Daniel R. Passeri, President and
Chief Executive Officer

Michael P. Gray, Chief Operating and
Chief Financial Officer

Changgeng Qian, Ph.D., M.D., Vice President,
Discovery and Preclinical Development

Mark W. Noel, Vice President, Technology Management and
Business Development

BOARD OF DIRECTORS

James R. McNab, Jr. - Chairman of the Board

Susan B. Bayh

Stephen K. Carter, M.D.

Joseph M. Davie, Ph.D., M.D.

Martyn D. Greenacre

Kenneth I Kaitin, Ph.D.

Daniel R. Passeri

James R. Tobin